Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis

British Journal of Cancer

Volumn 101, Issue 8, 2009, Pages 1282-1289

  Fluge, O ^a   Gravdal, K ^a   Carlsen, E ^b   Vonen, B ^c   Kjellevold, K ^d   Refsum, S ^e   Lilleng, R ^f   Eide, T J ^b   Halvorsen, T B ^g   Tveit, K M ^h   Otte, A P ⁱ   Akslen, L A ^a,j   Dahl, O ^a,j  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e Laboratory for Pathology AS   (Norway)

^f Buskerud Central Hospital   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j UNIVERSITY OF BERGEN   (Norway)

more..

Author keywords

Adjuvant chemotherapy; Colorectal cancer; EZH2; Immunehistochemistry; Ki 76; Prediction of outcome

Indexed keywords

ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; FLUOROURACIL; KI 67 ANTIGEN; LEVAMISOLE; POLYCOMB GROUP PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; COLON CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; LOADING DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM CANCER; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 70349958032     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605333     Document Type: Article

References (19)

1. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS (2003) Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21: 241-250
2. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351
3. Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, Soiland H, Janssen EA, Zur Hausen A (2009) Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 115: 241-254
4. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273
5. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22: 5323-5335
6. Brown DC, Gatter KC (2002) Ki67 protein: the immaculate deception? Histopathology 40: 2-11
7. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67: 547-556
8. Chen H, Rossier C, Antonarakis SE (1996) Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. Genomics 38: 30-37
9. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12: 1168-1174
10. Dahl O, Fluge O, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group (2009) Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 48: 368-376
11. De Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C (2007) Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 34: S37-S40
12. Kimura T, Tanaka S, Haruma K, Sumii K, Kajiyama G, Shimamoto F, Kohno N (2000) Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol 16: 55-64
13. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, Twito DI, Morton RF, Tschetter LK, Barlow JF (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7: 1447-1456
14. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Maillard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358
15. Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegard JN, Stenling R (1999) Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br J Cancer 79: 577-581
16. Salminen E, Palmu S, Vahlberg T, Roberts PJ, Soderstrom KO (2005) Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol 11: 3245-3249
17. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V (2004) Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23: 5759-5769
18. Van der Vlag J, Otte AP (1999) Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23: 474-478
19. Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, Jones J, Glass A, Lerner H, Lawrence W, Prager D, Wexler M, Evans J, Cruz A, Dimitrov N, Jochimsen P (1988) Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 80: 30-36 (Pubitemid 18076566)